Patents by Inventor Torben ØRNTOFT

Torben ØRNTOFT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MicroRNA-based method for early detection of prostate cancer in urine samples
    Patent number: 10400288
    Abstract: The present application concerns a new in vitro method for assessing the risk that a subject suffers from prostate cancer.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: September 3, 2019
    Assignees: Aarhus Universitet, Region Midtjylland, QIAGEN GmbH
    Inventors: Anni Rønfeldt Thomsen, Jacob Christian Fredsøe, Karina Dalsgaard Sørensen, Lars Kongsbak, Peter Mouritzen, Torben Ørntoft
  • Microrna-based method for assessing the prognosis of a prostate cancer patient
    Patent number: 10358681
    Abstract: The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, mi R-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, mi R-374b-5p, miR-615-3p and mi R-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: July 23, 2019
    Assignees: Aarhus Universitet, Region Midtjylland, QIAGEN GmbH
    Inventors: Anni Rønfeldt Thomsen, Helle Kristensen, Karina Dalsgaard Sørensen, Lars Kongsbak, Peter Mouritzen, Torben Ørntoft
  • A MICRORNA-BASED METHOD FOR ASSESSING THE PROGNOSIS OF A PROSTATE CANCER PATIENT
    Publication number: 20180044737
    Abstract: The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, miR-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, miR-374b-5p, miR-615-3p and miR-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 15, 2018
    Applicant: Exiqon A/S
    Inventors: Anni RØNFELDT THOMSEN, Helle KRISTENSEN, Karina DALSGAARD SØRENSEN, Lars KONGSBAK, Peter MOURITZEN, Torben ØRNTOFT
  • MICRORNA-BASED METHOD FOR EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES
    Publication number: 20180030542
    Abstract: The present application concerns a new in vitro method for assessing the risk that a subject suffers from prostate cancer.
    Type: Application
    Filed: February 5, 2016
    Publication date: February 1, 2018
    Inventors: Anni RØNFELDT THOMSEN, Jacob Christian FREDSØE, Karina DALSGAARD SØRENSEN, Lars KONGSBAK, Peter MOURITZEN, Torben ØRNTOFT